Brii Biosciences

Brii Biosciences made its initial public offering (IPO) on the Hong Kong stock exchange on Tuesday. The 111.6 million shares—priced at $2.86 each—will raise nearly $320 million to advance the Sino-American biotech’s pipeline of more than 10 product candidates focused on infectious and central nervous system diseases, according to a company press release.

Brii’s portfolio includes candidate therapies for Covid-19, hepatitis B, HIV and multidrug-resistant Gram-negative bacterial…

Brii Biosciences, VBI Vaccines and Vir Biotechnology jointly announced on Wednesday that the first patient has been dosed in a Phase 2 combination trial of a potential functional cure for chronic hepatitis B infection.

The companies are studying BRII-835 (VIR-2218), an investigational small interfering ribonucleic acid (siRNA) targeting hepatitis B virus (HBV), in combination with BRII-179 (VBI-2601), an investigational HBV immunotherapeutic, for the treatment of chronic HBV…

The state of the hunt:

Serum Institute of India will export Covishield doses to the United Kingdom.
  COVAX unveiled initial vaccine allocations, and numerous COVAX participants received their first shipments and began administering jabs.
  Bharat Biotech’s Covaxin demonstrated 81% efficacy against symptomatic disease in an interim Phase 3 analysis.

 

Vaccines


Approved or authorized vaccines
  
U.S. regulators completed their signoff…

The state of the hunt:

WHO issued its first EUL for a Covid-19 vaccine in recent days while Britain and the EMA authorized an additional jab and China and India cleared their first shots.
  Both Bharat Biotech and Pfizer claimed their respective vaccines are effective against newly identified SARS-CoV-2 variants.
  SII pledged to sell an initial 100 million doses to India at a “special price” of $2.74 each.

 

Vaccines


Approved or authorized…

The state of the hunt:

Moderna’s became the second Covid-19 vaccine to receive U.S. FDA Emergency Use Authorization.
  COVAX has secured nearly 2 billion doses of vaccines but faces a “very high” failure risk, according to Reuters.
  Canada, Saudi Arabia and the United States have begun immunization campaigns using Pfizer/BioNTech’s jab.

 

Vaccines


Approved or authorized vaccines
 
The U.S. FDA granted Emergency Use Authorization (EUA…

The world saw its 1 millionth case this week as companies continued to pursue Covid-19 solutions and many moved to scale up capacity.

Essential developments included:

Vaccines

On vaccines, Johnson & Johnson pledged this week that it would bring an “affordable” Covid-19 shot to the public “on a not-for-profit basis” for emergency pandemic use. It announced it has identified a lead candidate—Ad26 SARS-CoV-2—plus two investigational “backups,” and said it has begun scaling…

Newly formed AN2 Therapeutics announced in a debut press release last week that an investor group, including Adjuvant Capital, has provided $12 million in initial financing to support its infectious-disease drug catalog.

The California-based company also revealed a licensing deal with North Carolina–based startup Brii Biosciences, which plans to develop, manufacture and commercialize AN2’s clinical-stage antibiotic for multidrug-resistant tuberculosis for the Chinese market.